Skip to main content
. 2022 Apr 14;12:848187. doi: 10.3389/fonc.2022.848187

Table 1.

Patient clinical and pathological characteristics.

Characteristics All patients NE-BCT NS-BCT χ2/F p-value
N=3,460 N=1,730 N=1,730
Age at diagnosis(median) 62.21 ± 13.64 62.41 ± 13.60 62.02 ± 13.64 0.708 >0.05
Age 0.11 0.92
 <65 1,935 (55.9) 969 (56.0) 966 (55.8)
 ≧65 1,525 (44.1) 761 (44.0) 764 (44.2)
Race 0.112 0.946
 Non-Hispanic White 2,310 (66.8) 1,159 (67.0) 1,151 (66.5)
 Non-Hispanic Black 343 (9.9) 169 (9.8) 174 (10.1)
 Others 807 (23.3) 402 (23.2) 405 (23.4)
Year of diagnosis 0.131 0.717
 1998–2006 805 (23.3) 398 (23.0) 407 (23.5)
 2007–2015 2,655 (76.7) 1,332 (77.0) 1,323 (76.5)
Marital status 0.07 0.79
 Married 1,790 (51.7) 899 (52.0) 891 (51.5)
 Others 1,670 (48.3) 831 (48.0) 839 (48.5)
Laterality 0.14 0.71
 Left 1,819 (52.6) 915 (52.9) 904 (52.3)
 Right 1,641 (47.4) 815 (47.1) 826 (47.8)
Grade 0.057 0.972
 I 762 (22.0) 379 (21.9) 383 (22.1)
 II 1,640 (47.4) 819 (47.3) 821 (47.5)
 III+IV 1,058 (30.6) 532 (30.7) 526 (30.4)
ER Status 0.002 0.96
 Positive 2,875 (83.1) 1,437 (83.1) 1,438 (83.1)
 Negative 585 (16.9) 293 (16.9) 292 (16.9)
PR Status 0.01 0.91
 Positive 2,537 (73.3) 1,267 (73.2) 1,270 (73.4)
 Negative 923 (26.7) 463 (26.8) 460 (26.6)
T Stage 0.76 0.69
 T0–1 2,219 (64.1) 1,111 (64.2) 1,108 (64.1)
 T2 1,073 (31.0) 530 (30.6) 543 (31.4)
 T3–4 168 (4.9) 89 (5.1) 79 (4.6)
N Stage 0.41 0.81
 N0 2,441 (70.6) 1,229 (71.0) 1,212 (70.1)
 N1 827 (23.9) 406 (23.5) 421 (24.3)
 N2–3 192 (5.6) 95 (5.5) 97 (5.6)
Radiation 0.11 0.74
 Yes 2,335 (67.5) 1,172 (67.8) 1,163 (67.2)
 No 1,125 (32.5) 558 (32.3) 567 (32.8)
Chemotherapy 0.08 0.78
 Yes 1,190 (34.4) 591(34.2) 599 (34.6)
 No 2,270 (65.6) 1,139 (65.8) 1,131 (65.4)

NE-BCT, nipple-excising breast-conserving therapy; NS-BCT, nipple-sparing breast-conserving therapy; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; BCSD, breast-cancer-specific death; OCSD, other-cause-specific death.